The California health system is working with Canexia to assess if a triaged, in-house testing strategy improves outcomes, lowers cost, and reduces access inequities.
September 14, 2021
OncoHelix and Canexia Health, are partnering to help Canadian cancer patients gain access to precision genomic testing via their oncologist. Using a circulating tumour DNA (ctDNA) or “liquid biopsy” blood sample, the partnership allows for Canexia Health’s Follow It® ctDNA 38-gene panel to be accessed through OncoHelix for testing services.
September 3, 2021
Canexia Health CEO, Michael Ball, joined Bio Asia Pacific 2021 to discuss global expansion of the company’s liquid biopsy initiative, Project ACTT (Access to Cancer Testing & Treatment).
September 1, 2021
Personalized cancer treatment via targeted therapies is two-to-three times more effective than standard chemotherapy for patients with advanced or metastatic cancer.
August 10, 2021
Cancer patients have been heavily impacted by the ongoing COVID-19 pandemic. With thousands of tissue biopsies delayed and patients postponing clinic visits across Canada, increasing access to circulating tumour DNA (ctDNA) testing for targeted treatment selection has offered another option for oncologists.
August 4, 2021
July 20, 2021
Canexia Health recently sponsored a virtual roundtable, hosted by GenomeWeb, focused on disparities in access to precision oncology. Kellie Jack of Weill Cornell Medicine, Raymond Osarogiagbon of Baptist Cancer Center, Rachit Kumar of Maine General Medical Center, and Greg Tranah of Sutter Health discussed their perspectives working within small and large health systems across the US.
July 13, 2021
Liquid biopsy has become a useful tool for targeted cancer treatment selection.
June 22, 2021
Last year, by Precision Oncology News’ count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.
May 4, 2021
Microsatellites are short, repeating DNA segments that can play a major role in studying cancers.
Every Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.